|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-2-2
|
|
pubmed:abstractText |
Neuroendocrine differentiation of prostatic adenocarcinoma is a recognized phenomenon, which is believed to parallel tumor progression to hormone refractory state. Circulating CgA levels were shown to reflect neuroendocrine differentiation and were found to correlate with the stage and the state of hormone refractoriness. Hence, CgA may become a marker for diagnosis, monitoring and management of prostate cancer patients.
|
|
pubmed:language |
heb
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0017-7768
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
145
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
25-9, 78
|
|
pubmed:dateRevised |
2007-4-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16450720-Chromogranin A,
pubmed-meshheading:16450720-Chromogranins,
pubmed-meshheading:16450720-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:16450720-Humans,
pubmed-meshheading:16450720-Male,
pubmed-meshheading:16450720-Neoplasm Staging,
pubmed-meshheading:16450720-Prognosis,
pubmed-meshheading:16450720-Prostate-Specific Antigen,
pubmed-meshheading:16450720-Prostatic Neoplasms,
pubmed-meshheading:16450720-Reference Values,
pubmed-meshheading:16450720-Tumor Markers, Biological
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
[Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
|
|
pubmed:affiliation |
Department of Urology, Meir Medical Center, Kfar Saba. Leibovitchi@clalit.org.il
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
